Welcome to our dedicated page for Prenetics SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a company that sells DNA tests, builds multi-cancer detection panels, and even secures data on the blockchain can feel overwhelming. Prenetics’ SEC filings blend consumer-nutrition details with highly technical genomic disclosures, making it hard to spot what truly moves the stock.
Stock Titan solves that problem. Our AI turns Prenetics’ 300-page annual report 10-K into a digestible brief, flags segment revenue from IM8 supplements versus Insighta diagnostics, and alerts you to Prenetics insider trading Form 4 transactions the instant they hit EDGAR. Need the latest numbers? The platform autogenerates plain-language highlights from every Prenetics quarterly earnings report 10-Q filing and attaches context so you understand R&D spend on new genomic assays.
Wondering which disclosures matter most? Browse a dedicated feed that maps each filing type to real questions investors ask:
- 10-K & 10-Q – revenue by division, regulatory milestones, liquidity trends
- 8-K material events explained – clinical-trial readouts or blockchain partnerships
- Form 4 insider transactions real-time – see if executives buy before data releases
- Proxy statement executive compensation – incentives tied to cancer-test approvals
Every document arrives with AI-powered summaries, keyword search, and cross-links—so understanding Prenetics SEC documents with AI becomes a five-minute task, not a weekend project. Whether you’re looking for a Prenetics earnings report filing analysis or need a Prenetics annual report 10-K simplified, Stock Titan keeps you ahead of the curve.
Prenetics Global Limited furnished a Form 6-K noting it issued a press release announcing the pricing and subscription of its best efforts public offering. The press release is included as Exhibit 99.1. The report is signed by Chief Financial Officer Lo Hoi Chun on October 27, 2025.
Prenetics Global Limited launched a preliminary prospectus supplement for a primary offering of Class A Ordinary Shares and/or Pre-funded Warrants, each sold together with one Class A Warrant and one Class B Warrant. The Class A and Class B Warrants are exercisable immediately and will expire five years from issuance. The warrants and Pre-funded Warrants will be issued separately but are not being listed, so liquidity may be limited.
Dominari Securities LLC is engaged as exclusive placement agent on a reasonable best efforts basis, with cash fees of 8% of gross proceeds (reduced to 4% for company-introduced investors) and placement agent warrants equal to up to 6% of the securities sold (reduced to 2% for directed orders). Pre-funded Warrants are available to investors whose share purchases would otherwise exceed 4.99% (or, at the purchaser’s election, 9.99%) beneficial ownership. Net proceeds are intended for IM8 global expansion, development and implementation of the Company’s Bitcoin treasury strategy, working capital and general corporate purposes.
Prenetics Global Limited furnished a Form 6-K noting it issued a press release announcing a proposed public offering. The company states that the press release, dated October 24, 2025, is provided as Exhibit 99.1 to this report.
The filing lists the exhibit and includes the company’s authorization by Chief Financial Officer Lo Hoi Chun.
Prenetics Global Limited furnished Amendment No. 1 to Form 6-K, adding its condensed consolidated financial statements for the six months ended June 30, 2025 as Exhibit 99.2. The amendment supplements the September 12, 2025 Form 6-K that included business updates and unaudited Q2 results and does not change other information. This report is incorporated by reference into the company’s Form F-3 and Form S-8 registration statements.
On 1 Aug 2025, Prenetics Global Limited (NASDAQ: PRE) reported the results of an Extraordinary General Meeting via Form 6-K. Shareholders approved two resolutions:
- Proposal 1 – Authorised Share Capital Increase: the authorised capital rises from US$50,000 (33.3 m shares) to US$320,000 (213.3 m shares) at the unchanged par value of US$0.0015. This adds 160 m Class A shares, 12 m Class B convertible shares and 8 m undesignated shares. The motion passed with 4,250,875 votes FOR versus 503,820 AGAINST (≈78.7% support).
- Proposal 2 – Administrative Filing Authority: authorises the company’s registered office provider to file the amended charter with Cayman authorities. Passed with 4,744,054 FOR and only 14,922 AGAINST.
No financial results were disclosed. Approval materially expands the company’s capacity to issue new equity, signalling potential future capital raises and possible dilution for existing holders.
FAQ
What is the current stock price of Prenetics (PRE)?
What is the market cap of Prenetics (PRE)?
